Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Darrington, R Siobhan ^a   Campa, Victor M ^b   Walker, Marjorie M ^a   Bengoa Vergniory, Nora ^b   Gorrono Etxebarria, Irantzu ^b   Uysal Onganer, Pinar ^a   Kawano, Yoshiaki ^a,c   Waxman, Jonathan ^a   Kypta, Robert M ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CIC BIOGUNE   (Spain)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

androgen receptor; glycogen synthase kinase 3; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ANDROGEN RECEPTOR; BICALUTAMIDE; CHIR 99021; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GLEASON SCORE; GSK3A GENE; GSK3B GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; NEOPLASM GRADING; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84864125580     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27620     Document Type: Article

References (49)

1. Kaidanovich-Beilin O, Woodgett JR,. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 2011; 4: 40.
2. Zhou Y, Uddin S, Zimmerman T, et al. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 2008; 49: 1945-53.
3. Naito S, Bilim V, Yuuki K, et al. Glycogen synthase kinase-3β: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res 2010; 16: 5124-32.
4. Miyashita K, Kawakami K, Nakada M, et al. Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma. Clin Cancer Res 2009; 15: 887-97.
5. Mamaghani S, Patel S, Hedley DW,. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-κB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 2009; 9: 132.
6. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005; 334: 1365-73.
7. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, et al. Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006; 12: 5074-81.
8. Cao Q, Feng YJ,. Glycogen synthase kinase-3β (GSK-3β) promotes proliferation of ovarian cancer cells in vitro. Zhonghua Zhong Liu Za Zhi 2006; 28: 804-9.
9. Bilim V, Ougolkov A, Yuuki K, et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101: 2005-14.
10. Liao X, Thrasher JB, Holzbeierlein J, et al. Glycogen synthase kinase-3β activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004; 145: 2941-9.
11. Mazor M, Kawano Y, Zhu H, et al. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004; 23: 7882-92.
12. Rinnab L, Schutz SV, Diesch J, et al. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia 2008; 10: 624-34.
13. Schutz SV, Cronauer MV, Rinnab L,. Inhibition of glycogen synthase kinase-3β promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 2010; 109: 1192-200.
14. Zhu Q, Yang J, Han S, et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011; 71: 835-45.
15. Li R, Erdamar S, Dai H, et al. Cytoplasmic accumulation of glycogen synthase kinase-3β is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res 2009; 29: 2077-81.
16. Wilson W, III, Baldwin AS,. Maintenance of constitutive IκB kinase activity by glycogen synthase kinase-3α/β in pancreatic cancer. Cancer Res 2008; 68: 8156-63.
17. Piazza F, Manni S, Tubi LQ, et al. Glycogen synthase kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer 2010; 10: 526.
18. Wang Z, Smith KS, Murphy M, et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205-9.
19. Force T, Woodgett JR,. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009; 284: 9643-7.
20. Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, et al. Distinct molecular regulation of glycogen synthase kinase-3α isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. J Biol Chem 2011; 286: 13470-80.
21. Soutar MP, Kim WY, Williamson R, et al. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem 2010; 115: 974-83.
22. Salas TR, Kim J, Vakar-Lopez F, et al. Glycogen synthase kinase-3β is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 2004; 279: 19191-200.
23. Wang L, Lin HK, Hu YC, et al. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3β in prostate cells. J Biol Chem 2004; 279: 32444-52.
24. Schutz SV, Schrader AJ, Zengerling F, et al. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 2011; 6: e25341.
25. Lu Y, Muller M, Smith D, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011; 30: 4567-77.
26. Shin S, Wolgamott L, Yu Y, et al. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 2011; 108: E1204-E1213.
27. Campa VM, Kypta RM,. Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells. Biol Direct 2011; 6: 4.
28. Castano Z, Gordon-Weeks PR, Kypta RM,. The neuron-specific isoform of glycogen synthase kinase-3β is required for axon growth. J Neurochem 2010; 113: 117-30.
29. Wagman AS, Johnson KW, Bussiere DE,. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10: 1105-37.
30. Zhang J, Gonit M, Salazar MD, et al. C/EBPα redirects androgen receptor signaling through a unique bimodal interaction. Oncogene 2010; 29: 723-38.
31. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
32. Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10: 321-30.
33. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86.
34. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
35. Kawano Y, Diez S, Uysal-Onganer P, et al. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer. Br J Cancer 2009; 100: 1165-74.
36. Uysal-Onganer P, Kawano Y, Caro M, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 2010; 9: 55.
37. Veeman MT, Slusarski DC, Kaykas A, et al. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol 2003; 13: 680-5.
38. Doble BW, Woodgett JR,. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-86.
39. Dokken BB, Henriksen EJ,. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats. Am J Physiol Endocrinol Metab 2006; 291: E207-E213.
40. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
41. Ryan CJ, Tindall DJ,. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-8.
42. Gravina GL, Marampon F, Di Staso M, et al. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 2010; 70: 1166-78.
43. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
44. Lin HK, Yeh S, Kang HY, et al. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-5.
45. Yang J, Takahashi Y, Cheng E, et al. GSK-3β promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci 2010; 123: 861-70.
46. Meares GP, Jope RS,. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J Biol Chem 2007; 282: 16989-7001.
47. Gioeli D, Black BE, Gordon V, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006; 20: 503-15.
48. Grisouard J, Mayer D,. Specific involvement of glycogen synthase kinase-3 in the function and activity of sex steroid hormone receptors reveals the complexity of their regulation. J Steroid Biochem Mol Biol 2009; 117: 87-92.
49. Eldar-Finkelman H, Martinez A,. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 2011; 4: 32.